Myriad Genetics to Participate in Morgan Stanley Global Healthcare Conference
05 sept. 2023 08h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced management will participate in the...
Myriad Genetics and Onsite Women’s Health Partner to Help More Women Understand Breast Cancer Risk
22 août 2023 09h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Onsite Women’s Health, a leading national provider of...
Myriad Genetics to Host Investor Day on September 19, 2023
17 août 2023 16h05 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will host an Investor Day at the newly constructed Dr....
Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris®
15 août 2023 07h05 HE
|
Myriad Genetics, Inc.
Prolaris is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1 SALT LAKE CITY, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc.,...
Myriad Genetics and Intermountain Health Participate in ComboMATCH, a National Clinical Trial to Advance Cancer Treatment
08 août 2023 16h05 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Intermountain Precision Genomics, part of the...
Myriad Genetics Announces Enhancements to the GeneSight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status
07 août 2023 16h05 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, announced enhancements to the GeneSight® Psychotropic test,...
Myriad Genetics Reports Second Quarter 2023 Financial Results and Reaffirms 2023 Revenue and Adjusted EPS Guidance; Generates the Fourth Consecutive Quarter of Double-Digit Year-Over-Year Testing Volume Growth
03 août 2023 16h05 HE
|
Myriad Genetics, Inc.
Highlights: Second quarter testing volume grew 17% year-over-year, excluding contributions from the SneakPeek® Early Gender DNA Test.In the second quarter: Hereditary cancer test volumes grew 20%...
Myriad Genetics to Release Second Quarter Financial Results on Aug. 3, 2023
27 juil. 2023 16h05 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, July 27, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its second quarter earnings conference call on...
Myriad Genetics Announces Inclusion of Breast Density to MyRisk® with RiskScore® Breast Cancer Risk Assessment
24 juil. 2023 08h00 HE
|
Myriad Genetics, Inc.
RiskScore is the first validated risk model that includes breast density, personal/family history and genetic markers This comprehensive model is expected to identify more patients that could benefit...
Myriad Genetics Announces New $90 Million Asset-Based Credit Facility
06 juil. 2023 08h30 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, July 06, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that it has established a new $90 million...